Preclinical studies have demonstrated that STING agonist ADCs achieve strong tumor growth inhibition with minimal systemic immune activation and can synergize with immune checkpoint inhibitors, highlighting their potential to enhance efficacy while mitigating toxicities seen with free STING agonists. The gene discussed is STING1; the disease is neoplasm.